- ►diabetesjournals.org HE Lebovitz, M Kreider, MI Freed - Diabetes Care, 2002 - Am Diabetes Assoc OBJECTIVE—Troglitazone treatment has been associated with idiosyncratic
hepatic reaction leading to hepatic failure and death in some patients. This
raises questions regarding whether all thiazolidinediones or peroxisomal ... Cited by 149 - Related articles - BL Direct - All 8 versions
- ►adisonline.com [PDF] AJ Scheen - Drug safety, 2001 - ingentaconnect.com Abstract Decreased insulin sensitivity plays a major role in various human
diseases, particularly type 2 diabetesmellitus,and isassociated with ahigher
risk ofathero- sclerosis and cardiovascular complications. ... Cited by 83 - Related articles - BL Direct - All 7 versions
- ►annals.org [PDF] LD May, JH Lefkowitch, MT Kram, DE Rubin - Annals of internal medicine, 2002 - Am Coll Physicians Louis D. May, MD; Jay H. Lefkowitch, MD; Michael T. Kram, MD; and David E.
Rubin, MD ... Background: Pioglitazone is an oral hypoglycemic agent in the
thiazolidinedione class. Only one case of hepatotoxicity related to this ... Cited by 86 - Related articles - All 6 versions
HE Gouda, A Khan, J Schwartz, RI Cohen - The American Journal of Medicine, 2001 - Elsevier An 82-year-old man was admitted with a 3-week history of malaise, nausea, and
generalized weakness. He had a history of diabetes, coronary artery disease,
cholecystectomy, and a chromophilic pituitary adenoma that was treated ... Cited by 31 - Related articles - BL Direct - All 6 versions
K Maeda - Annals of internal medicine, 2001 - ncbi.nlm.nih.gov 1: Ann Intern Med. 2001 Aug 21;135(4):306. Hepatocellular injury in a patient
receiving pioglitazone. Maeda K. Publication Types ... Cited by 69 - Related articles - BL Direct
- ►annals.org [PDF] J Al-Salman, H Arjomand, DG Kemp, M Mittal - Annals of internal medicine, 2000 - Am Coll Physicians Jameela Al-Salman, MD; Heider Arjomand, MD; David G. Kemp, MD; and Manoj Mittal,
MD ... Background: Rosiglitazone maleate (Avandia, SmithKline Beecham,
Philadelphia, Pennsylvania) is a new oral hypo- glycemic agent approved for ... Cited by 181 - Related articles - BL Direct - All 6 versions
LM Forman, DA Simmons, RH Diamond - Annals of internal medicine, 2000 - Am Coll Physicians Lisa M. Forman, MD; David A. Simmons, MD; and Robert H. Diamond, MD ...
Background: Rosiglitazone maleate is the second ap- proved oral hypoglycemic
agent of the thiazolidinedione class. The first, troglitazone, has been ... Cited by 180 - Related articles - BL Direct - All 7 versions
FJ Gómez-Perez, G Fanghänel-Salmón, JA … - Diabetes/Metabolism Reviews - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 90 - Related articles - BL Direct - All 4 versions
- ►diabetesjournals.org G Viberti, SE Kahn, DA Greene, WH Herman, … - Diabetes Care, 2002 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—A Diabetes Outcome Progression Trial (ADOPT) is a
randomized, double-blind, parallel-group study consisting of a screening visit,
a 4-week placebo run-in, a 4-year treatment period, and an observational ... Cited by 165 - Related articles - BL Direct - All 14 versions
Y Miyazaki, L Glass, C Triplitt, M Matsuda, … - Diabetologia, 2001 - Springer The thiazolidinediones represent a new class of insu- lin sensitizing agents for
the treatment of Type II (non-insulin-dependent) diabetes mellitus. The origi-
nal drug in this class, troglitazone, has been shown to ameliorate insulin ... Cited by 204 - Related articles - BL Direct - All 5 versions
